SEINE BIO · PEPTIDE PROFILE

Cagrilintide

Amylin analogue · metabolic research

Investigational

Get to know the name, understand the evidence, and prepare a more informed conversation.

What is Cagrilintide?

An amylin analogue being studied for weight management. It follows a different receptor pathway from GLP-1 medicines. Clinical development does not establish approval or availability. Developer pipeline.

THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026

Inside the science of Cagrilintide.

Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.

Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.

Overview

Cagrilintide is a long-acting amylin analogue investigated for weight management. It follows a different biological pathway from a GLP-1 agonist, which is why researchers study it alone and in combinations. Cagrilintide and CagriSema are related but separate subjects: one is a molecule, while the other is a specific combination development program.

Community Use

PeptideDosages publishes a cagrilintide protocol page. Its existence documents a community calculation source, not an approved prescribing standard. No exact Peptidepedia.org cagrilintide profile was verified for this draft, so claims are not attributed to one. Interest in combining appetite pathways should be separated from evidence for a finished combination.

Doses, Durations & Cycles

Informal biohacking protocols and published regimens. Attributed website reports for education, not medical recommendations. Multiple publications document circulation; they do not establish a safe dose or validate a cycle.

Protocol reference — Cagrilintide
Route / formulation	Dose / reported phases	Frequency	Duration / break	Notes and source
Subcutaneous injection	Trial arms: 0.3, 0.6, 1.2, 2.4 or 4.5 mg weekly.	Once weekly in the cited trial	26-week treatment period, including up to 6 weeks of escalation; 6-week follow-up without treatment Break: No informal off-cycle established by this source	Human study regimen Lau et al., Lancet 2021; once-weekly cagrilintide phase 2 trial
Subcutaneous	0.25 mg in weeks 1–4, 0.5 mg in weeks 5–8, 1 mg in weeks 9–12, 1.7 mg in weeks 13–16 and 2.4 mg from week 17.	Once weekly	16-week escalation, then continued target dosing; no total course specified. Break: Not stated	Published informal biohacking claim Peptide Dosing Protocols
Subcutaneous	0.25 mg in weeks 1–4; 0.5 then 1 mg during weeks 5–12; 1.7 mg in weeks 13–16; 2.4 mg from week 17.	Once weekly	Escalation through week 16; continued dosing from week 17, with no fixed end. Break: Not stated	Published informal biohacking claim Longeva

Important context: The lowest and highest trial arms are not an established starting dose and safe maximum. No average dose is established.

Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.

The phase 2 dose-finding trial compared several weekly groups during 26 weeks of treatment, followed by observation without treatment. Escalation was part of the study. The table retains those source-specific distinctions; it does not supply an approved consumer starting dose or a cycle for adding cagrilintide to another medicine.

Research Findings

The randomized study enrolled adults with overweight or obesity without diabetes and included placebo and liraglutide comparisons. It examined body-weight change, safety and tolerability. A dose-finding design asks which exposures merit further development; it is not equivalent to demonstrating that any independently sourced formulation can be safely used.

U.S. Approval & Access

FDA states that cagrilintide cannot be used in compounding under federal law and is not a component of an FDA-approved medicine. A pharmacy name or medical consultation does not override that status. A legitimate research program has its own enrollment and oversight requirements.

What It Does in the Body

Amylin is involved in satiety-related physiology. Cagrilintide was designed for prolonged activity in that signaling system. A distinct mechanism explains the research question, but does not prove that combining it with a GLP-1 drug is appropriate for any reader. Complementary biology still needs formulation-specific clinical testing. Reliable onset, peak clinical benefit and duration after stopping are not established for routine care by the sources reviewed; the length of a trial is not the duration of a guaranteed effect.

Benefits & Reported Experiences

The phase 2 trial found greater mean weight reduction with cagrilintide than placebo. Results varied across the studied groups and were collected over months. They cannot establish a guaranteed monthly rate of loss or the effect of an unofficial blend. Review who completed treatment and how missing data were handled alongside efficacy.

Side Effects & Risks

Nausea and other gastrointestinal adverse events were prominent in the trial. The safety information remains tied to the monitored population and studied product. Online symptom reports cannot establish reliable frequencies or characterize interactions. Discuss any history of severe digestive problems and current appetite- or glucose-related treatments with a qualified clinician.

Delivery Options

The human study evaluated subcutaneous administration using an investigational formulation. That tells you what the researchers tested, not how to prepare or use a community product. Any genuine study supplies its own instructions and follow-up. This article does not convert study doses into preparation or injection guidance.

Product Quality & Storage

Confirm the exact substance rather than treating an abbreviated seller label as a pharmaceutical specification. Cagrilintide alone, a mixture and a developer’s combination program differ in composition and evidence. The ability to calculate an amount from a vial label says nothing about authorization, sterility or whether the content matches the label. No verified patient-use storage specification is supplied by the cited research. Research materials cannot inherit an approved medicine’s stability or storage instructions; an authorized program must provide its product-specific conditions.

Combinations & Interactions

Cagrilintide-plus-semaglutide research is addressed separately under CagriSema. Evidence for that controlled combination cannot validate a home mixture, a different ratio or an additional third compound. This guide therefore supplies no stacking schedule. Bring the proposed combination to a clinician as a question, rather than as a protocol to approve unchanged.

Talking With Your Provider

Ask what the current research can answer, whether a legitimate study fits your circumstances and which approved alternatives are available now. Your goal may be addressed through established weight-care options even when cagrilintide is unsuitable or unavailable. A consultation should clarify the choices and uncertainty rather than promise a research substance.

Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.

Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.

Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.

Questions worth bringing to your appointment.

Are there alternatives that address my goal?
If treatment is appropriate, what monitoring and follow-up would I need?
Could my health history or current medicines change the risks?

A clinician may recommend a different option—or no medication—after assessing your individual circumstances.

Saved discussion topics 0

Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.

Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.

Bring your curiosity. Start a conversation.

Create a free account to request review and manage purchases. Paid membership is optional. Clinical review and authorization still apply where required, and any separate service charges are shown before you agree to pay.

Create a free account ↗

This educational information is free to read. Create a free account to request review of your care goals. Neither an account nor paid membership guarantees a prescription, access to the named compound or research enrollment.

Educational profile · U.S. context · October 7, 2026. This page does not provide personalized medical advice, dosing, or injection instructions.

Bring your saved topics to your care team.

Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.

Choose saved topics for review →